Table 9.
Characteristics of intravenous liposomal drug products
| Product | Drug substance | Lipid Excipients | Indication |
|---|---|---|---|
| Abelcet | Amphotericin B | DMPC | Invasive fungal infections |
| DMPG | |||
| AmBisome | Amphotericin B | HSPC | Aspergillus-, Candida- and/or Cryptococcus species infections |
| DSPG | |||
| Cholesterol | Visceral leishmaniasis | ||
| Alpha-tocopherol | |||
| DaunoXome | Daunorubicin citrate | DSPC | Advanced HIV-associated Kaposi's sarcoma |
| Cholesterol | |||
| Doxil/Caelyx | Doxorubicin HCl/sulphate | MPEG-DSPE | AIDS-related Kaposi's sarcoma Ovarian cancer Multiple myeloma |
| HSPC | |||
| Cholesterol | |||
| Marqibo | Vincristine sulphate | Egg SM | Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia |
| Cholesterol | |||
| Mepact | MTP-PE, Mifartumide | POPC | Osteosarcoma |
| DOPS | |||
| Myocet | Doxorubicin HCl/citrate | Egg PC | Metastatic breast cancer |
| Cholesterol | |||
| Visudyne, Verteporfin for injection | Benzoporphyrin | DMPC | Exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) |
| Egg PG | Subfoveal choroidal neovascularisation secondary to pathological myopia. | ||
| Ascorbyl palmitate (Butylated-hydroxytoluene) |